© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Daunorubicin Hydrochloride stands out as a well-known anthracycline antibiotic, commonly used as a chemotherapeutic agent for certain types of cancer, especially leukemia. Its presence in hematology wards around the world often means the difference between a treatment path and a series of dead ends. This compound comes from the Streptomyces species, tweaked in laboratories to harness potent anti-tumor activity. Having spent time in pharmaceutical research, the first impression of daunorubicin hydrochloride is always its distinctive red-orange hue, a marker of many anthracycline derivatives, yet this color belies the stringent handling it demands, both in the lab and clinic.
Looking at the material under typical lighting, it often appears as a crystalline powder, sometimes seen in flakes, rarely as solid pearls. There is flexibility in handling depending on supplier or intended use; yet, most chemists and pharmacists prefer its powder form for simplicity in measuring and dissolving. The texture often feels fine and cohesive, with a certain dryness, making it prone to spreading dust if mishandled.
Daunorubicin Hydrochloride’s molecular formula is C27H30ClNO10, and its structure reveals anthraquinone rings fused to an amino sugar. The presence of chloride changes the solubility and stability profile, and these factors play a crucial role in safe storage and transportation. The molecular weight clocks in at around 563.98 g/mol, a figure burned into the minds of anyone responsible for compounding doses by hand. The density hovers close to 1.6 g/cm³, a value worth remembering since small quantities weigh more than they appear. The solid dissolves easily in water, especially when prepared as an injectable solution, though this process requires careful pH buffering due to the compound’s sensitivity to degradation outside its ideal range.
Pharmaceutical-grade daunorubicin hydrochloride demands strict adherence to purity, typically above 98%, with residual solvents, endotoxins, and water content scrupulously monitored. The structure is robust under normal pharmaceutical conditions, but exposure to heat, light, or strong acids damages it, leading to a loss of potency and the potential for creating toxic byproducts. The crystals display an off-red shimmer under bright lab lights, which helps in identifying contaminants or improper synthesis. Each vial should specify its HS Code; common entries include 2934999090, reflecting its position among organic therapeutic agents, a classification enforced for cross-border trade and supply chain accuracy.
Working with daunorubicin hydrochloride means recognizing real risks. The powder is hazardous if inhaled, ingested, or if it comes into contact with skin. Hospital pharmacies require use of negative pressure hoods and full PPE. Long-term exposure has links with cytotoxic effects and tissue necrosis. Most hazardous chemical guides highlight its potential to cause irreversible damage to corneal or mucous tissues. Once mixed into a solution for infusion, extra care is vital since aerosolized droplets still pose risks to staff. Spills need immediate cleanup using specialized kits; there’s no room for complacency given the cost of human error. Regulatory agencies demand clear labeling: “Hazardous, harmful if swallowed, toxic by contact or inhalation.” Teams train annually to manage accidental exposures or leaks, a regimen that demonstrates the substance’s risk profile in practical, daily settings.
Daunorubicin hydrochloride production starts with fermentation of select Streptomyces strains, followed by multiple purification steps to reach the level required for medicinal use. The process borrows elements from antibiotic manufacturing, yet each batch needs careful pH control, solvent removal, and crystallization. Quality raw materials extend beyond the microbiological source to include reagents, buffers, and solvents, each checked for interaction profiles. From experience, inconsistencies in raw material quality inevitably reduce yield, so best-practice manufacturers stick with vetted suppliers and invest in regular audits of feedstock purity. Each intermediate compound receives characterization through chromatography and mass spectrometry, not only for compliance but to ensure patient safety at the end of the line.
Strong protocols address every step: clear chemical labeling, separation between hazardous and non-hazardous zones, documented temperature logs during storage, and formalized spill management procedures. Facilities now automate dispensing and mixing as much as practical, limiting exposure for workers. Disposal systems tie in with hazardous waste contractors, making illegal discharge unlikely. In my own work, tech transfer meetings always focus on these practicalities, as even minor lapses in storage or waste stream management create outsized risks. Innovation continues in automated reconstitution and single-dose packaging, both aimed at making life safer for frontline staff. Social responsibility requires remembering that behind every vial is a chain of handlers and patients whose health hinges on strict adherence to these procedures, from factory floor to treatment room.
